This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

LSX USA Congress
Life Science Executive Partnering
Congress Sept 16-17, Forums Sept 15, 2025Thomas Michael Menino Convention & Exhibition Center, Boston, USA
Menu
Key Sessions
Michelle Li
Strategic Alliances in Biopharma: Unlocking Growth Through Collaborative Partnerships
Bristol Myers Squibb
Maha Radhakrishnan
Thinking like an Investor: The Risk-Adjusted Cost of Generating Value in R&D
Sofinnova Investments
Michaela Tolman
Rewiring the Future: Innovations Driving Progress in Neuroscience Across Life Sciences
Pfizer
Rich Tannenbaum
Innovation, Investment and the Future of Regenerative Liver Cell Therapies
Ouroboros Group
Irene Blat
Next-Gen Oncology: Partnering for Progress to Bring New Therapies to Market
Servier Pharmaceuticals
Christopher Tan
From Spark to Success: Partnering in Early-Stage Pharma Innovation
Merck
Kurt Haggstrom
Putting the Tech in Medtech: How Big Tech are Staking Their Claim in the Healthcare Sector
Synchron
Jim Robertson
The Future of Neuromodulation is Here: The Partnership Between Neuroscience and Neurotechnology
Nu-Life Solutions
keyboard_arrow_right

Day 2 – Wednesday, 17 Sept 2025 - ET (Eastern Time, GMT-05:00)

keyboard_arrow_leftSearch & Filter
search
Day 2 – Wednesday, 17 Sept 2025 - ET (Eastern Time, GMT-05:00)
search
8:00am - 8:55am
Registration & Breakfast
Showing 3 of 3 Streams
8:55am - 9:00am
LSX Welcome Address
9:00am - 9:50am
Strategic Alliances in Biopharma: Unlocking Growth Through Collaborative Partnerships
  • Michelle Li - VP & Head, BD&L Transactions, Bristol Myers Squibb
  • Aaron Gardner - Partner, Latham & Watkins
  • Siobhan Pomeroy - VP, Corporate Development, Gilead Sciences
  • Irene Pasquali - Head of Global BD, Respiratory, Chiesi
9:50am - 10:30am
Making Clinical Trials Boring: How Living Human Tissues and AI-Scale Data Predict Drug Performance Before Human Trials
  • Andrei Georgescu - CEO, Vivodyne
  • Julie O'Shaughnessy - COO, Vivodyne
10:30am - 11:00am
MORNING BREAK
9:00am - 9:25am
Harnessing Adipocyte Energetics to Fight Obesity & Related Disorders
  • Olivier Boss - Chief Scientific Officer and Founder, Energesis Pharmaceuticals
9:25am - 9:50am
Harnessing Gastrointestinal Nutrient-Sensing for Comprehensive Metabolic Regulation
  • Steffen-Sebastian Bolz - CSO, Aphaia Pharma
9:50am - 10:15am
Transient Coating of Upper GI Tract Mimics the Effects of RYGB
  • David Pass - CEO, Altrix Bio
10:15am - 10:45am
MORNING BREAK
8:55am - 9:00am
LSX Welcome Address
9:00am - 9:50am
Putting the Tech in Medtech: How Big Tech are Staking Their Claim in the Healthcare Sector
  • Kurt Haggstrom - CCO, Synchron
  • Carolina Aguilar - CEO & Co-Founder, INBRAIN Neuroelectronics
  • Jenny Barba - Co-Founder & Managing Partner, Features Capital
  • Marion Webb - Managing Editor, Citeline
9:50am - 10:30am
The Future of Neuromodulation is Here: The Partnership Between Neuroscience and Neurotechnology
  • Jim Robertson - CEO, Nu-Life Solutions
10:30am - 11:00am
MORNING BREAK
Showing 5 of 5 Streams
11:00am - 11:50am
Smart Capital: Rethinking Biotech Fundraising for Agility and Survival
  • Niranjan Sardesai - President & CEO, Founder, Geneos Therapeutics
  • Anula Jayasuriya - Co-Founder, Kidron Capital
  • Sohail Zaidi - CEO, Ananda Scientific Inc
  • Elena Itskovich - Founding General Partner, Nest Catalyst Ventures
  • Paresh Kumar - VP, Biotech Private Equity, Ally Bridge Group
11:50am - 12:40pm
Thinking like an Investor: The Risk-Adjusted Cost of Generating Value in R&D
  • Maha Radhakrishnan - Executive Partner, Sofinnova Investments
  • Madhav Gurijala - SVP, SSI Strategy
  • Alison Schecter - SVP, Clinical Development, Mineralys Therapeutics
  • Christian Howell - CEO, Cognito Therapeutics
12:40pm - 1:20pm
Innovation, Investment and the Future of Regenerative Liver Cell Therapies
  • Rich Tannenbaum - Chief Investment Officer, Ouroboros Group
  • Anna Argo - CBO, Cytotheryx
  • John Swart - CEO, Cytotheryx
  • Natalie Torin - Partner, Woods Capital
11:00am - 11:50am
Next-Gen Oncology: Partnering for Progress to Bring New Therapies to Market
  • Irene Blat - Senior Director, Search & Evaluation, Servier Pharmaceuticals
  • Joel Klappenbach - Executive Director, Oncology Business Development, Pfizer
  • Venky Raghavan - Executive Director, Search & Evaluation, Oncology, Novartis
  • Jonah Comstock - Editor in Chief, pharmaphorum
11:50am - 12:40pm
From Spark to Success: Partnering in Early-Stage Pharma Innovation
  • Christopher Tan - Executive Director, BD&L, Merck
  • Kyle LaHucik - Senior Reporter, Endpoints News
  • Ashley Zehnder - CEO, Fauna Bio
  • Mankit Law - Senior Director – BD, Search & Evaluation, GSK
  • Gene Yau - Executive Director, Corporate Development & Strategy, Nimbus Therapeutics
  • Jeremy O’Hanlon - Executive Director, Global BD, Daiichi-Sankyo
12:40pm - 1:20pm
Platforms, Not Products: Unlocking the Next Wave of Biotech Innovation
  • Amber Salzman - CEO, Epicrispr
  • Scott Jordan - Founder & CEO, S. Jordan Associates
  • Jae Won Kim - Partner, Adelphi Ventures
  • Errik Anderson - Founder & CEO, Alloy Therapeutics
  • Lihua Zheng - CEO, Z-Star Therapeutics
11:00am - 11:50am
Biotech in 2025: Rethinking Early Commercialisation for a Rapidly Changing Market
  • Tim Sullivan - CBO, Infinimmune
  • Andy Tincu - VP, Solutions Development, Syneos Health
  • Raven Lin - CEO, Pilatus Biosciences
  • Michelle Chen - CEO, Form Bio
11:50am - 12:40pm
Thriving in Turbulence: Commercial Mastery for the Next Biotech Era
  • Michael Rice - SVP, Head of Advanced Therapeutics, Lumanity
  • Anna Argo - CBO, Cytotheryx
  • Johan Liwing - CEO, Lipigon Pharmaceuticals
  • Jacob Hansen - CEO, Vesper Bio
12:40pm - 1:20pm
The Equation for Maturation: Biotech Requirements to Achieve Scale
  • Rachel Ravens - CEO, 42Genetics
  • Robert Albarano - Partner, Arthur D. Little
  • Jukka Muhonen - VP Business Development, Orphagen Pharmaceuticals
  • Alex Kadet - CBO, Gero
  • Ben Yerxa - President, Opus Genetics
  • Alexander Rotenberg - Co-founder, Galibra Neuroscience
11:10am - 11:35am
High-throughput in vivo screening to discover novel targets for adipose-directed therapies
  • Joanne Hsieh, PhD - Head of Metabolism, Gordian Biotechnology
11:35am - 12:00pm
siRNA-based Therapeutics Targeting INHBE and ACVR1C Obesity-Driving Genes
  • Lucas BonDurrant - Principle Scientist, Alnylam
12:00pm - 12:25pm
Inhibiting miR-22 To Promote Energy Expenditure
  • Riccardo Panella - CSO & Scientific Founder, Resalis Therapeutics
12:25pm - 12:50pm
Exploring siRNA Combinations for Enhanced Therapeutic Benefits in Obesity
  • Michelle Ngai - Senior Scientist, Arrowhead Pharmaceuticals
11:00am - 11:50am
Flipping the Script: How Medtech is Responding to the Rise of Techmed
  • Amir Zur - Executive Director, Regional Head of R&D Engineering, Digital Unit, Olympus Corporation
  • Taiba Quraishi - Innovation Accelerator Lead, Alexion
  • Ben Naovarat - Investor, Cybernetix
  • Michael Dillhyon - General Partner, Sarasota Growth Ventures
  • Sheila Phicil - Founder & CEO, Phicil-itate Change
11:50am - 12:40pm
Going Global: The Realities of Expanding into New Markets
  • Mike Alvarez - CEO, Glooko
  • Chris Springate - CEO, ARC Medical
  • Ritesh Patel - Chief Growth Officer, Doceree
  • Giles Hamilton - Operating Partner, New Growth Advisors
12:40pm - 1:20pm
Unlocking Strategic Partnerships: How To Engage Tier 1 Medtech and Pharma’s Biggest Players
  • Nate Harrington - Managing Partner, Philips Ventures
  • Ilana Gotlib - Strategy & Business Development, Independent
  • Jim Parshall - Executive Director, Drug Delivery R&D, Eli Lilly and Company
  • Andrew Baker-Campbell - Co-Founder & Chair, LEX Diagnostics
  • Matt Pullan - Managing Director, LSX
1:20pm - 2:20pm
LUNCH BREAK
Showing 2 of 2 Streams
2:20pm - 3:10pm
Uncommon Minds, Unseen Opportunities: How Diversity in Thought Brings New Medicines and Technologies to Market
  • Steven Fuller - Founder & Director, Race in STEM
  • Leslie Sam - President, Leslie Sam & Associates
  • Téa Romero - Account Management, Transperfect
  • Tamika Jackson - Executive Director & Founder, The Beautiful Way Foundation
3:10pm - 4:00pm
Rewiring the Future: Innovations Driving Progress in Neuroscience Across Life Sciences
  • Michaela Tolman - Commercial Development Lead – Inflammation & Immunology, Pfizer
  • Sohail Zaidi - CEO, Ananda Scientific Inc
  • David Donabedian - Executive Partner, Longwood Fund
  • Christian Howell - CEO, Cognito Therapeutics
  • Marc Jones - CEO, Altoida
2:20pm - 2:50pm
Keynote Presentation: Reshaping Consumption: The Ripple Effect of Obesity Therapeutics On The Food market
  • Reviewing the impact of the obesity therapeutics on consumer behaviour
  • Discussing future changes to the food industry as anti-obesity drugs progress, from ingredient sourcing to retail dynamics
  • Brandon McFadden - Professor Food Policy Economics, University of Arkansas
2:50pm - 3:40pm
Keynote Panel: Whole System Impact of Obesity Therapeutics - Addressing Comorbidities and Beyond

  • Discussing the influence of the obesity therapeutics on full patient health and addressing global demand

  • How is GLP-1R modulation being harnessed to treat broader diseases?

  • What next steps must be taken to better predict wider beneficial health outcomes of obesity therapeutics?

  • How is the industry working together to manage the global surge in GLP-1/ obesity drug products?

  • Camille Bedrosian - CMO, Amylyx Pharmaceuticals
  • Mimoun Ayoub - Senior VP, Global Head of Sales, Corden Pharma
  • Vipin Garg - CEO, Altimmune
  • Ashley Zehnder - CEO, Fauna Bio
  • Alice Gilman - COO, R3 Biotechnologies
4:00pm - 4:05pm
Close of Congress
Pharma BD Leaders Forum
NextDay 2 Showcases
Filter
Streams
Formats
Choose Day